

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: **Callitas Health Inc. (Callitas)**

Trading Symbol: LILY

Number of Outstanding Listed Securities: **32,462,095**

Date: December 4, 2017

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CSE.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Formed in early 2015, Callitas Health Inc, is a clinical-stage company developing innovative technologies for obesity, weight management and Female Health & Wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J's LLC, the Company distributes ToConceive, a FDA cleared fertility product.

Callitas trades on the Canadian Securities Exchange (CSE) under the ticker symbol "LILY" as well as on the OTC as "MPHMD" and FWB (Frankfurt Stock Exchange) as "T3F3."

Callitas Therapeutics is an integrated clinical stage pharmaceutical development corporation with an OTC products division in the Fertility Care & Female/Male Sexual Wellness space. The specific drug product(s) under development are segmented into separate operating LLC's for JV/project specific funding/partnering & operations outside of the parent public company. Currently Callitas wholly owns 100% of the OTC Products Division & CT Development Companies 2, 3 & 4 and 85% of CT Development 1 (inventor & outside investor/angel funding allocated at 15%).

- OTC Products Division- Fertility Care, Female & Male Sexual Wellness, etc (commercialized and pipeline products list and accompanying information available upon request).
 - CT Development 1- Orphan Drug Development for Urea Cycle Disorders- Submitted ODD/RPD Designation Requests to US FDA. Response expected in 60-90 day timeframe from 11/27/17.
 - CT Development 2- C-103 (modified Orlistat drug product for obesity)- Positive pIND Meeting Letter, Development GAP analysis and Drug Commercialization Plan Available.
 - CT Development 3- Extrinsa (topical tadalafil for Female Sexual Arousal Disorder)- Positive pIND Meeting Letter, Development GAP analysis and Drug Commercialization Plan Available.
 - CT Development 4- "Cannamint" (Oral/Buccal arginine/menthol enhanced delivery of CBD/THC)- Product overview available (Not US FDA regulated).
 - Other products and technologies being evaluated (FS).
2. Provide a general overview and discussion of the activities of management. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- 1) The core management team for Callitas Health Inc (CEO, CFO & COO) have been focused on expanding the current distribution of OTC products beyond a few markets in Asia and now South America. The team's business strategy to segment and partner with select organizations focusing on weight management, female wellness and orphan drugs; these initiatives can be defined as successful and on target.

2) Callitas has successfully filed it's Orphan Drug Designation and Rare Pediatric Disease Request Designations with the US FDA in late November, 2017. Timeline to response is roughly 60-90 days.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None applicable at this time.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None applicable at this time.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

No additional business relationships have been signed at this time.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None applicable at this time.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

No additional business relationships have been signed at this time.

8. Describe the acquisition of new customers or loss of customers.

None applicable at this time.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Callitas received notice of publication for its ToConceive trademark from the USPTO, as well as a positive response for the allowed claims in the patent application for Male Infertility.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None at this time.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Callitas Health Inc. did not become a party to any legal proceedings during this period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No indebtedness occurred during this period.

14. Provide details of any securities issued and options or warrants granted.

The Company also announced that it has recently granted 750,000 options pursuant to its incentive stock option agreement to directors, officers and employees. These options are exercisable at \$0.40 for a period of 5 years.

15. Provide details of any loans to or by Related Persons.

There were no loans made to or by related parties or persons during this period.

Provide details of any changes in directors, officers or committee members.

None at this time.

16. Discuss any trends that are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None applicable during this period.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: December 4, 2017

Gary Thompson CEO

Gary Thompson

Signature

President and CEO

Official Capacity

<i>Issuer Details</i> Name of Issuer Callitas Health Inc.	For Month End November, 2017	Date of Report December 4, 2017
Issuer Address 187 Pavilion Pkwy, Suite 200, Newport Kentucky 41071		
City/Province/Postal Code Vancouver, B.C. V7X 1B1	Issuer Fax No.	Issuer Fax No.
Contact Name Gary A. Thompson	Contact Position President & CEO	Contact Telephone No. 1-859-868-3131
Contact Email Address info@callitas.com	Web Site Address www.callitas.com	